about
Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.Successful radiopeptide targeting of metastatic anaplastic meningioma: case reportEffect of endobronchial valve therapy on pulmonary perfusion and ventilation distribution.The value of intravoxel incoherent motion model-based diffusion-weighted imaging for outcome prediction in resin-based radioembolization of breast cancer liver metastases.The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment.Iodine-131-lipiodol therapy in hepatic tumours.The role of SPECT/CT in radioembolization of liver tumours.Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT.Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour.Yttrium-90 Radioembolization of Advanced, Unresectable Breast Cancer Liver Metastases-A Single-Center Experience.Incidence and risk factors of early arterial blood flow stasis during first radioembolization of primary and secondary liver malignancy using resin microspheres: an initial single-center analysis.Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience.Theranostics in nuclear medicine practiceEarly prediction of tumour response to PRRT. The sequential change of tumour-absorbed doses during treatment with 177Lu-octreotate.Role of high-resolution ultrasound and PET/CT imaging for preoperative characterization of sentinel lymph nodes in cutaneous melanoma.Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study.Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness <1.00 mm) on the basis of a long-term follow-up.The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects.Residual activity after radioembolization of liver tumours with 90Y resin microspheres. A safe calculation method.Dual-time F-18 FDG-PET/CT imaging for diagnosis of occult non-Hodgkin lymphoma in a patient with esophageal cancer.Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma.Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.Splenic infarction mimicking a necrotizing metastasis of malignant melanoma on F-18 FDG PET/CT.Passive cigarette smoking increases isoprostane formation.Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.Diagnostic accuracy of [99mTc]Tc-Sestamibi in the assessment of thyroid nodules.Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.It is time to move forward into the era of Theranostics.Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness >4.00 mm): outcome analysis from a single institution.Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer.Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response.Review: The role of radiolabeled DOTA-conjugated peptides for imaging and treatment of childhood neuroblastoma.Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion.
P50
Q33410193-13218ACF-BE76-4DF3-A43F-E399CAEC1FDEQ33410798-1B8D3813-6163-4BD5-A898-554BED6D4D10Q33441176-58BB9833-CECC-4F41-858D-4A45D7A1F870Q35206154-8EB97183-7170-4089-88D2-CC52E7F4845DQ35231269-C6BFBB01-4D57-4CC3-A598-319E67BA5C59Q37082835-24315FED-F44F-4F52-9006-10AF96D5F4FBQ37775809-506A4E49-6469-4EFB-8316-CC3DC3475315Q37888140-2183ACCB-2FB7-40B3-89E1-D13A2870BB56Q38180004-8E968313-D66E-4C99-9F1D-A16C145E1A85Q38652008-E1D69197-0C1A-4C84-BEB2-948D70D4CB4CQ38861197-D629F8C7-3E45-42D7-853A-CF90479B07D3Q38936576-8FCFDEC8-4134-4920-B29B-BE67E2DD0FD0Q39556605-8B87F25D-463D-4CCE-98F5-25B266AC4891Q40330206-741D895B-3004-424A-A70C-833C148298FFQ42370609-58451425-7512-4FB7-ABEA-4048446DAFA3Q42373162-00CCF75D-370D-4C61-BA55-27E430AF2793Q43531010-F742827B-D4F6-4212-88E8-CC96A7D1B4E5Q43611026-DB58A7FA-E719-4D33-9EB9-06532CAB9F1CQ43738534-F915A642-F526-4A3C-8CAB-D7ED290FD048Q45180237-0F003F8D-9FB3-46E0-B7FC-E22068510AA4Q45332662-211F3565-C0AD-466A-887B-0E54A0535753Q45850578-085F4448-36A8-40DB-84C5-43694D8471FBQ46057840-1DCA4B7F-6F40-49AD-A8A9-DBA673CA23F3Q46379125-DC38DAD3-FEBE-492B-8322-C027797DD93CQ46454210-D26250BE-7F9B-4FBE-90D6-E4B5D0E7E5D7Q46470448-B3CD0DCE-BCEA-4C61-8494-6B4539ED1892Q46705444-9BAD82C3-8211-4CE2-BA01-F3C0A1F9B40DQ46925547-2880A422-757D-45A7-872C-0A44F2E77236Q47128358-E95655B6-B15A-4A3C-850F-2C1C995622A1Q47158291-58F80A24-CBF2-4D13-9D65-70725F935E73Q47653267-9B599527-9429-47A3-9A6D-DD98E23E8222Q47705593-BE130A38-EF5E-483A-A5FC-50CFCCB26B57Q47726575-04F3C3B5-0635-4F07-AD5C-A5950C9FA595Q48063139-64CF54F4-5761-48CC-AE50-D257076F562DQ48190592-EB00E762-8F9A-4DA4-82DB-B7480EE98755Q48257941-93D6578E-2889-42EF-8E51-E03EEE32276BQ48323017-EA141DD4-4A1D-42B1-93FF-C24241162500Q48568337-F5938D24-A436-4558-AE07-6BC729EC4EADQ49892722-1748F5C3-F160-48F7-81C4-B807F6FB02D5Q49992971-AB8499BC-20D0-4652-80E8-B375BCFC5BEB
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Hojjat Ahmadzadehfar
@ast
Hojjat Ahmadzadehfar
@de
Hojjat Ahmadzadehfar
@en
Hojjat Ahmadzadehfar
@es
Hojjat Ahmadzadehfar
@nl
Hojjat Ahmadzadehfar
@sl
type
label
Hojjat Ahmadzadehfar
@ast
Hojjat Ahmadzadehfar
@de
Hojjat Ahmadzadehfar
@en
Hojjat Ahmadzadehfar
@es
Hojjat Ahmadzadehfar
@nl
Hojjat Ahmadzadehfar
@sl
prefLabel
Hojjat Ahmadzadehfar
@ast
Hojjat Ahmadzadehfar
@de
Hojjat Ahmadzadehfar
@en
Hojjat Ahmadzadehfar
@es
Hojjat Ahmadzadehfar
@nl
Hojjat Ahmadzadehfar
@sl
P214
P227
P106
P21
P213
0000 0001 1531 1395
P214
P227
P31
P496
0000-0002-0393-5309
P569
1973-01-01T00:00:00Z
P7859
viaf-168233431